Based on the numerically better outcomes in immunotherapy trials, the patients' positive PD-L1 status, and the low percentage of severe irAE to immunotherapy, first-line systemic therapy with pembrolizumab was initiated with close monitoring for immune dysfunction and viral flare-ups. Here, CD274 is linked to immune system disorder.